Abstract
Protozoa and helminths have by far the greatest impact in terms of morbidity worldwide. The status of protozoa and helminths control, both in human and veterinary medicine, is challenged as the current medications against these parasites are losing their efficacy due to increasing and even further spreading drug resistance. Despite this alarming statement and the high burden imposed by parasites, research progress in parasitic diseases lags behind many other infectious diseases. Recent innovative technologies may significantly impact parasite diagnostics and their control in the near future, catalyzed by a better knowledge in drug resistance mechanisms. The present chapter review drug resistance assays in major protozoan and helminthic diseases, point-of-care tests and multiplexing assays for drug resistance testing, and opportunities for innovations in the field.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hotez PJ, Alvarado M, Basanez MG, Bolliger I, et al. The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8, e2865.
Taylor SM, Juliano JJ. Artemisinin combination therapies and malaria parasite drug resistance: the game is afoot. J Infect Dis. 2014;210:335–7.
Dondorp AM, Nosten F, Yi P, Das D, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.
Carrara VI, Zwang J, Ashley EA, Price RN, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One. 2009;4, e4551.
Denis MB, Tsuyuoka R, Lim P, Lindegardh N, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006;11:1800–7.
Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, et al. Surveillance of the efficacy of artesunate and mefloquine combination for the treatment of uncomplicated falciparum malaria in Cambodia. Trop Med Int Health. 2006;11:1360–6.
Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungmanee D, et al. In vivo sensitivity monitoring of mefloquine monotherapy and artesunate-mefloquine combinations for the treatment of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int Health. 2006;11:211–19.
Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Malar J. 2011;10:268.
Jambou R, Legrand E, Niang M, Khim N, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005;366:1960–3.
Yang H, Liu D, Yang Y, Fan B, et al. Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. Trans R Soc Trop Med Hyg. 2003;97:226–8.
Blair P, Diemert D. Update on prevention and treatment of intestinal helminth infections. Curr Infect Dis Rep. 2015;17:465.
Bennett A, Guyatt H. Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Parasitol Today. 2000;16:71–4.
Albonico M, Bickle Q, Ramsan M, Montresor A, et al. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ. 2003;81:343–52.
Albonico M, Engels D, Savioli L. Monitoring drug efficacy and early detection of drug resistance in human soil-transmitted nematodes: a pressing public health agenda for helminth control. Int J Parasitol. 2004;34:1205–10.
Schwab AE, Boakye DA, Kyelem D, Prichard RK. Detection of benzimidazole resistance-associated mutations in the filarial nematode Wuchereria bancrofti and evidence for selection by albendazole and ivermectin combination treatment. Am J Trop Med Hyg. 2005;73:234–8.
Flohr C, Tuyen LN, Lewis S, Minh TT, et al. Low efficacy of mebendazole against hookworm in Vietnam: two randomized controlled trials. Am J Trop Med Hyg. 2007;76:732–6.
Vercruysse J, Behnke JM, Albonico M, Ame SM, et al. Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis. 2011;5, e948.
Osei-Atweneboana MY, Awadzi K, Attah SK, Boakye DA, et al. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis. 2011;5, e998.
Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis. 2007;1, e114.
McCall LI, McKerrow JH. Determinants of disease phenotype in trypanosomatid parasites. Trends Parasitol. 2014;30:342–9.
Chagas CJR., Memórias do Instituto Oswaldo Cruz. 1909. p. 159–218.
Zingales B, Miles MA, Campbell DA, Tibayrenc M, et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol. 2012;12:240–53.
Zingales B, Andrade SG, Briones MR, Campbell DA, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz. 2009;104:1051–4.
Gorlin J, Rossmann S, Robertson G, Stallone F, et al. Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening. Transfusion. 2008;48:531–40.
Bahia-Oliveira LM, Gomes JA, Cancado JR, Ferrari TC, et al. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14–30 years ago. J Infect Dis. 2000;182:634–8.
Cancado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo. 2002;44:29–37.
Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81:755–9.
Trischmann TM. Natural and acquired resistance to Trypanosoma cruzi. Adv Exp Med Biol. 1983;162:365–82.
Murta SM, Nogueira FB, Dos Santos PF, Campos FM, et al. Differential gene expression in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Acta Trop. 2008;107:59–65.
Veloso VM, Carneiro CM, Toledo MJ, Lana M, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz. 2001;96:1005–11.
Barrett MP, Croft SL. Management of trypanosomiasis and leishmaniasis. Br Med Bull. 2012;104:175–96.
Molina I, Salvador F, Sanchez-Montalva A. Posaconazole versus benznidazole for chronic Chagas’ disease. N Engl J Med. 2014;371:966.
Veiga-Santos P, Li K, Lameira L, de Carvalho TM, et al. SQ109, a new drug lead for chagas disease. Antimicrob Agents Chemother. 2015;59:1950–61.
Moraes CB, Giardini MA, Kim H, Franco CH, et al. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development. Sci Rep. 2014;4:4703.
Pena I, Pilar Manzano M, Cantizani J, Kessler A, et al. New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource. Sci Rep. 2015;5:8771.
Martinez-Mayorga K, Byler KG, Ramirez-Hernandez AI, Terrazas-Alvares DE. Cruzain inhibitors: efforts made, current leads and a structural outlook of new hits. Drug Discov Today. 2015.
Soeiro Mde N, de Souza EM, da Silva CF, Batista Dda G, et al. In vitro and in vivo studies of the antiparasitic activity of sterol 14alpha-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother. 2013;57:4151–63.
Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A. 2008;105:5022–7.
Hall BS, Wilkinson SR. Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother. 2012;56:115–23.
Hall BS, Bot C, Wilkinson SR. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem. 2011;286:13088–95.
Murta SM, Romanha AJ. In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole. Parasitology. 1998;116(Pt 2):165–71.
Murta SM, Gazzinelli RT, Brener Z, Romanha AJ. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol. 1998;93:203–14.
Camandaroba EL, Reis EA, Goncalves MS, Reis MG, Andrade SG. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop. 2003;36:201–9.
Teston AP, Monteiro WM, Reis D, Bossolani GD, et al. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon. Trop Med Int Health. 2013;18:85–95.
Rego JV, Duarte AP, Liarte DB, de Carvalho Sousa F, et al. Molecular characterization of Cyclophilin (TcCyP19) in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Exp Parasitol. 2015;148:73–80.
Mejia-Jaramillo AM, Fernandez GJ, Palacio L, Triana-Chavez O. Gene expression study using real-time PCR identifies an NTR gene as a major marker of resistance to benzonidazole in Trypanosoma cruzi. Parasit Vectors. 2011;4:169.
Buckner FS, Wilson AJ, White TC, Van Voorhis WC. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob Agents Chemother. 1998;42:3245–50.
Dos Santos FM, Caldas S, de Assis Cau SB, Crepalde GP, et al. Trypanosoma cruzi: induction of benznidazole resistance in vivo and its modulation by in vitro culturing and mice infection. Exp Parasitol. 2008;120:385–90.
Murta SM, Krieger MA, Montenegro LR, Campos FF, et al. Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol Biochem Parasitol. 2006;146:151–62.
Nogueira FB, Krieger MA, Nirde P, Goldenberg S, et al. Increased expression of iron-containing superoxide dismutase-A (TcFeSOD-A) enzyme in Trypanosoma cruzi population with in vitro-induced resistance to benznidazole. Acta Trop. 2006;100:119–32.
Rego JV, Murta SM, Nirde P, Nogueira FB, et al. Trypanosoma cruzi: characterisation of the gene encoding tyrosine aminotransferase in benznidazole-resistant and susceptible populations. Exp Parasitol. 2008;118:111–17.
Campos MC, Leon LL, Taylor MC, Kelly JM. Benznidazole-resistance in Trypanosoma cruzi: evidence that distinct mechanisms can act in concert. Mol Biochem Parasitol. 2014;193:17–9.
Mejia AM, Hall BS, Taylor MC, Gomez-Palacio A, et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population. J Infect Dis. 2012;206:220–8.
Wilkens S. Structure and mechanism of ABC transporters. F1000Prime Rep. 2015;7:14.
Rice AJ, Park A, Pinkett HW. Diversity in ABC transporters: type I, II and III importers. Crit Rev Biochem Mol Biol. 2014;49:426–37.
Campos MC, Castro-Pinto DB, Ribeiro GA, Berredo-Pinho MM, et al. P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance. Parasitol Res. 2013;112:2341–51.
Franco J, Ferreira RC, Ienne S, Zingales B. ABCG-like transporter of Trypanosoma cruzi involved in benznidazole resistance: gene polymorphisms disclose inter-strain intragenic recombination in hybrid isolates. Infect Genet Evol. 2015;31:198–208.
Saye M, Miranda MR, di Girolamo F, de los Milagros Camara M, Pereira CA. Proline modulates the Trypanosoma cruzi resistance to reactive oxygen species and drugs through a novel D, L-proline transporter. PLoS One. 2014;9, e92028.
Kaul S, Sharma SS, Mehta IK. Free radical scavenging potential of L-proline: evidence from in vitro assays. Amino Acids. 2008;34:315–20.
Vincent IM, Creek D, Watson DG, Kamleh MA, et al. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog. 2010;6, e1001204.
Rajao MA, Furtado C, Alves CL, Passos-Silva DG, et al. Unveiling benznidazole’s mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. Environ Mol Mutagen. 2014;55:309–21.
Campos FM, Liarte DB, Mortara RA, Romanha AJ, Murta SM. Characterization of a gene encoding alcohol dehydrogenase in benznidazole-susceptible and -resistant populations of Trypanosoma cruzi. Acta Trop. 2009;111:56–63.
Muelas-Serrano S, Nogal-Ruiz JJ, Gomez-Barrio A. Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes. Parasitol Res. 2000;86:999–1002.
Moreno M, D’Avila DA, Silva MN, Galvao LM, et al. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem Inst Oswaldo Cruz. 2010;105:918–24.
Luna KP, Hernandez IP, Rueda CM, Zorro MM, et al. In vitro susceptibility of Trypanosoma cruzi strains from Santander, Colombia, to hexadecylphosphocholine (miltefosine), nifurtimox and benznidazole. Biomedica. 2009;29:448–55.
Bustamante JM, Tarleton RL. Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov. 2011;6:653–61.
Lewis MD, Fortes Francisco A, Taylor MC, Burrell-Saward H, et al. Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection. Cell Microbiol. 2014;16:1285–300.
Lewis MD, Francisco AF, Taylor MC, Kelly JM. A new experimental model for assessing drug efficacy against Trypanosoma cruzi infection based on highly sensitive in vivo imaging. J Biomol Screen. 2015;20:36–43.
Hoare CA. Nagana. Trans R Soc Trop Med Hyg. 1971;65:531–2.
Cook GC. Sir David Bruce’s elucidation of the aetiology of nagana—exactly one hundred years ago. Trans R Soc Trop Med Hyg. 1994;88:257–8.
FIND, FIND Communications. 2013.
Matovu E, Kazibwe AJ, Mugasa CM, Ndungu JM, Njiru ZK. Towards point-of-care diagnostic and staging tools for human african trypanosomiaisis. J Trop Med. 2012;2012:340538.
Wery M, Burke J. Human “healthy carriers” of Trypanosoma (brucei type) discovered by immunofluorescence test in the Republique Democratique du Congo. Trans R Soc Trop Med Hyg. 1972;66:332–3.
Jamonneau V, Ilboudo H, Kabore J, Kaba D, et al. Untreated human infections by Trypanosoma brucei gambiense are not 100% fatal. PLoS Negl Trop Dis. 2012;6, e1691.
Bacchi CJ, Garofalo J, Ciminelli M, Rattendi D, et al. Resistance to DL-alpha-difluoromethylornithine by clinical isolates of Trypanosoma brucei rhodesiense. Role of S-adenosylmethionine. Biochem Pharmacol. 1993;46:471–81.
Iten M, Mett H, Evans A, Enyaru JC, et al. Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D, L-alpha-difluoromethylornithine. Antimicrob Agents Chemother. 1997;41:1922–5.
Phillips MA, Coffino P, Wang CC. Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. Implications for enzyme turnover and selective difluoromethylornithine inhibition. J Biol Chem. 1987;262:8721–7.
Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, et al. Fexinidazole—a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010;4, e923.
Jacobs RT, Nare B, Wring SA, Orr MD, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011;5, e1151.
Wenzler T, Yang S, Braissant O, Boykin DW, et al. Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis. Antimicrob Agents Chemother. 2013;57:5330–43.
Gilbert IH. Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter. Parasitology. 2014;141:28–36.
Barrett MP, Vincent IM, Burchmore RJ, Kazibwe AJ, Matovu E. Drug resistance in human African trypanosomiasis. Future Microbiol. 2011;6:1037–47.
Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, et al. Research and reports in tropical medicine. 2012. p. 93–101.
Alirol E, Schrumpf D, Amici Heradi J, Riedel A, et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: medecins sans frontieres experience in the democratic Republic of the Congo. Clin Infect Dis. 2013;56:195–203.
Carter NS, Fairlamb AH. Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature. 1993;361:173–6.
Maser P, Sutterlin C, Kralli A, Kaminsky R. A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science. 1999;285:242–4.
Munday JC, Tagoe DN, Eze AA, Krezdorn JA, et al. Functional analysis of drug resistance-associated mutations in the Trypanosoma brucei adenosine transporter 1 (TbAT1) and the proposal of a structural model for the protein. Mol Microbiol. 2015.
Matovu E, Geiser F, Schneider V, Maser P, et al. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol Biochem Parasitol. 2001;117:73–81.
Stewart ML, Burchmore RJ, Clucas C, Hertz-Fowler C, et al. Multiple genetic mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes. Eukaryot Cell. 2010;9:336–43.
Matovu E, Stewart ML, Geiser F, Brun R, et al. Mechanisms of arsenical and diamidine uptake and resistance in Trypanosoma brucei. Eukaryot Cell. 2003;2:1003–8.
Shahi SK, Krauth-Siegel RL, Clayton CE. Overexpression of the putative thiol conjugate transporter TbMRPA causes melarsoprol resistance in Trypanosoma brucei. Mol Microbiol. 2002;43:1129–38.
Alibu VP, Richter C, Voncken F, Marti G, et al. The role of Trypanosoma brucei MRPA in melarsoprol susceptibility. Mol Biochem Parasitol. 2006;146:38–44.
Munday JC, Eze AA, Baker N, Glover L, et al. Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. J Antimicrob Chemother. 2014;69:651–63.
Baker N, Glover L, Munday JC, Aguinaga Andres D, et al. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc Natl Acad Sci U S A. 2012;109:10996–1001.
Graf FE, Ludin P, Wenzler T, Kaiser M, et al. Aquaporin 2 mutations in Trypanosoma brucei gambiense field isolates correlate with decreased susceptibility to pentamidine and melarsoprol. PLoS Negl Trop Dis. 2013;7, e2475.
Barrett MP, Zhang ZQ, Denise H, Giroud C, Baltz T. A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity. Mol Biochem Parasitol. 1995;73:223–9.
Carter NS, Berger BJ, Fairlamb AH. Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J Biol Chem. 1995;270:28153–7.
de Koning HP, Anderson LF, Stewart M, Burchmore RJ, et al. The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in african trypanosomes. Antimicrob Agents Chemother. 2004;48:1515–19.
De Koning HP. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol Pharmacol. 2001;59:586–92.
de Koning HP. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. Trends Parasitol. 2008;24:345–9.
Bridges DJ, Gould MK, Nerima B, Maser P, et al. Loss of the high-affinity pentamidine transporter is responsible for high levels of cross-resistance between arsenical and diamidine drugs in African trypanosomes. Mol Pharmacol. 2007;71:1098–108.
Ortiz D, Sanchez MA, Quecke P, Landfear SM. Two novel nucleobase/pentamidine transporters from Trypanosoma brucei. Mol Biochem Parasitol. 2009;163:67–76.
Bacchi CJ, Garofalo J, Mockenhaupt D, McCann PP, et al. In vivo effects of alpha-DL-difluoromethylornithine on the metabolism and morphology of Trypanosoma brucei brucei. Mol Biochem Parasitol. 1983;7:209–25.
Vincent IM, Creek DJ, Burgess K, Woods DJ, et al. Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei. PLoS Negl Trop Dis. 2012;6, e1618.
Phillips MA, Wang CC. A Trypanosoma brucei mutant resistant to alpha-difluoromethylornithine. Mol Biochem Parasitol. 1987;22:9–17.
Alsford S, Eckert S, Baker N, Glover L, et al. High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature. 2012;482:232–6.
Sokolova AY, Wyllie S, Patterson S, Oza SL, et al. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother. 2010;54:2893–900.
Likeufack AC, Brun R, Fomena A, Truc P. Comparison of the in vitro drug sensitivity of Trypanosoma brucei gambiense strains from West and Central Africa isolated in the periods 1960–1995 and 1999–2004. Acta Trop. 2006;100:11–6.
Vansterkenburg EL, Coppens I, Wilting J, Bos OJ, et al. The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop. 1993;54:237–50.
Pepin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol. 1994;33:1–47.
Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol. 1995;35:93–127.
Kazibwe AJ, Nerima B, de Koning HP, Maser P, et al. Genotypic status of the TbAT1/P2 adenosine transporter of Trypanosoma brucei gambiense isolates from Northwestern Uganda following melarsoprol withdrawal. PLoS Negl Trop Dis. 2009;3, e523.
Tran T, Napier G, Rowan T, Cordel C, et al. Development and evaluation of an ITS1 “Touchdown” PCR for assessment of drug efficacy against animal African trypanosomosis. Vet Parasitol. 2014;202:164–70.
Moti Y, De Deken R, Thys E, Van Den Abbeele J, et al. PCR and microsatellite analysis of diminazene aceturate resistance of bovine trypanosomes correlated to knowledge, attitude and practice of livestock keepers in South-Western Ethiopia. Acta Trop. 2015;146:45–52.
Faccio L, Da Silva AS, Gressler LT, Tonin AA, et al. Susceptibility of Brazilian isolates of Trypanosoma evansi to suramin sodium: test in experimentally infected mice. Exp Parasitol. 2013;134:309–12.
Raz B, Iten M, Grether-Buhler Y, Kaminsky R, Brun R. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro. Acta Trop. 1997;68:139–47.
Gould MK, Vu XL, Seebeck T, de Koning HP. Propidium iodide-based methods for monitoring drug action in the kinetoplastidae: comparison with the Alamar Blue assay. Anal Biochem. 2008;382:87–93.
Stewart ML, Krishna S, Burchmore RJ, Brun R, et al. Detection of arsenical drug resistance in Trypanosoma brucei with a simple fluorescence test. Lancet. 2005;366:486–7.
Wells EA. The importance of mechanical transmission in the epidemiology of nagana: a review. Trop Anim Health Prod. 1972;4:74–88.
Desquesnes M, Dia ML. Mechanical transmission of Trypanosoma congolense in cattle by the African tabanid Atylotus agrestis. Exp Parasitol. 2003;105:226–31.
Hoppenheit A, Steuber S, Bauer B, Ouma EM, et al. Host preference of tsetse: an important tool to appraise the Nagana risk of cattle in the cotton zone of Mali. Wien Klin Wochenschr. 2010;122 Suppl 3:81–6.
Codjia V, Mulatu W, Majiwa PA, Leak SG, et al. Epidemiology of bovine trypanosomiasis in the Ghibe valley, southwest Ethiopia 3 Occurrence of populations of Trypanosoma congolense resistant to diminazene, isometamidium and homidium. Acta Trop. 1993;53:151–63.
Mulugeta W, Wilkes J, Mulatu W, Majiwa PA, et al. Long-term occurrence of Trypanosoma congolense resistant to diminazene, isometamidium and homidium in cattle at Ghibe. Ethiopia Acta Trop. 1997;64:205–17.
Peregrine AS, Gray MA, Moloo SK. Cross-resistance associated with development of resistance to isometamidium in a clone of Trypanosoma congolense. Antimicrob Agents Chemother. 1997;41:1604–6.
Van den Bossche P, Chigoma D, Shumba W. The decline of anti-trypanosomal antibody levels in cattle after treatment with trypanocidal drugs and in the absence of tsetse challenge. Acta Trop. 2000;77:263–70.
Vitouley HS, Sidibe I, Bengaly Z, Marcotty T, et al. Is trypanocidal drug resistance a threat for livestock health and production in endemic areas? Food for thoughts from Sahelian goats infected by Trypanosoma vivax in Bobo Dioulasso (Burkina Faso). Vet Parasitol. 2012;190:349–54.
Mungube EO, Vitouley HS, Allegye-Cudjoe E, Diall O, et al. Detection of multiple drug-resistant Trypanosoma congolense populations in village cattle of south-east Mali. Parasit Vectors. 2012;5:155.
Sow A, Sidibe I, Bengaly Z, Marcotty T, et al. Field detection of resistance to isometamidium chloride and diminazene aceturate in Trypanosoma vivax from the region of the Boucle du Mouhoun in Burkina Faso. Vet Parasitol. 2012;187:105–11.
Wilkes JM, Mulugeta W, Wells C, Peregrine AS. Modulation of mitochondrial electrical potential: a candidate mechanism for drug resistance in African trypanosomes. Biochem J. 1997;326(Pt 3):755–61.
Eisler MC, Brandt J, Bauer B, Clausen PH, et al. Standardised tests in mice and cattle for the detection of drug resistance in tsetse-transmitted trypanosomes of African domestic cattle. Vet Parasitol. 2001;97:171–82.
Murray M, Murray PK, McIntyre WI. An improved parasitological technique for the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg. 1977;71:325–6.
Delespaux V, Geysen D, Van den Bossche P, Geerts S. Molecular tools for the rapid detection of drug resistance in animal trypanosomes. Trends Parasitol. 2008;24:236–42.
Chitanga S, Marcotty T, Namangala B, Van den Bossche P, et al. High prevalence of drug resistance in animal trypanosomes without a history of drug exposure. PLoS Negl Trop Dis. 2011;5, e1454.
Munday JC, Rojas Lopez KE, Eze AA, Delespaux V, et al. Functional expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for diminazene uptake. Int J Parasitol Drugs Drug Resist. 2013;3:69–76.
Teka IA, Kazibwe AJ, El-Sabbagh N, Al-Salabi MI, et al. The diamidine diminazene aceturate is a substrate for the high-affinity pentamidine transporter: implications for the development of high resistance levels in trypanosomes. Mol Pharmacol. 2011;80:110–16.
Whitelaw DD, Gault EA, Holmes PH, Sutherland IA, et al. Development of an enzyme-linked immunosorbent assay for the detection and measurement of the trypanocidal drug isometamidium chloride in cattle. Res Vet Sci. 1991;50:185–9.
Eisler MC, Gault EA, Smith HV, Peregrine AS, Holmes PH. Evaluation and improvement of an enzyme-linked immunosorbent assay for the detection of isometamidium in bovine serum. Ther Drug Monit. 1993;15:236–42.
Eisler MC, Elliott CT, Holmes PH. A simple competitive enzyme immunoassay for the detection of the trypanocidal drug isometamidium. Ther Drug Monit. 1996;18:73–9.
Karanja WM, Mdachi RE, Murilla GA. A competitive enzyme-linked immunosorbent assay for diminazene. Acta Trop. 2002;84:75–81.
Salih NA, van Griensven J, Chappuis F, Antierens A, et al. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease? Trop Med Int Health. 2014;19:146–52.
Nyakundi PM, Rashid JR, Wasunna KM, Were JB, et al. Problems in the treatment of kala-azar: case report. East Afr Med J. 1995;72:406–8.
Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am J Trop Med Hyg. 2009;80:580–2.
Soni P, Prasad N, Khandelwal K, Ghiya BC, et al. Unresponsive cutaneous leishmaniasis and HIV co-infection: report of three cases. Indian J Dermatol Venereol Leprol. 2011;77:251.
Zijlstra EE. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses. PLoS Negl Trop Dis. 2014;8, e3258.
Orsini M, Canela JR, Disch J, Maciel F, et al. High frequency of asymptomatic Leishmania spp. infection among HIV-infected patients living in endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hyg. 2012;106:283–8.
Shaked-Mishan P, Ulrich N, Ephros M, Zilberstein D. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J Biol Chem. 2001;276:3971–6.
Gourbal B, Sonuc N, Bhattacharjee H, Legare D, et al. Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem. 2004;279:31010–17.
Marquis N, Gourbal B, Rosen BP, Mukhopadhyay R, Ouellette M. Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania. Mol Microbiol. 2005;57:1690–9.
Mukherjee A, Boisvert S, Monte-Neto RL, Coelho AC, et al. Telomeric gene deletion and intrachromosomal amplification in antimony-resistant Leishmania. Mol Microbiol. 2013;88:189–202.
Brochu C, Wang J, Roy G, Messier N, et al. Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother. 2003;47:3073–9.
Legare D, Richard D, Mukhopadhyay R, Stierhof YD, et al. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem. 2001;276:26301–7.
Dey S, Ouellette M, Lightbody J, Papadopoulou B, Rosen BP. An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae. Proc Natl Acad Sci U S A. 1996;93:2192–7.
Manzano JI, Garcia-Hernandez R, Castanys S, Gamarro F. A new ABC half-transporter in Leishmania major is involved in resistance to antimony. Antimicrob Agents Chemother. 2013;57:3719–30.
Garg M, Goyal N. MAPK1 of Leishmania donovani modulates antimony susceptibility by down regulating P-glycoprotein efflux pumps. Antimicrob Agents Chemother. 2015.
Rai Bhaskar S, Goel SK, Nath Dwivedi U, et al. Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS One. 2013;8, e74862.
Mukherjee A, Padmanabhan PK, Singh S, Roy G, et al. Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother. 2007;59:204–11.
Singh R, Kumar D, Duncan RC, Nakhasi HL, Salotra P. Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites. Int J Antimicrob Agents. 2010;36:50–7.
Jeddi F, Mary C, Aoun K, Harrat Z, et al. Heterogeneity of molecular resistance patterns in antimony-resistant field isolates of Leishmania species from the western Mediterranean area. Antimicrob Agents Chemother. 2014;58:4866–74.
Singh N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J Med Res. 2006;123:411–22.
Kazemi-Rad E, Mohebali M, Khadem-Erfan MB, Hajjaran H, et al. Overexpression of ubiquitin and amino acid permease genes in association with antimony resistance in Leishmania tropica field isolates. Korean J Parasitol. 2013;51:413–19.
t’Kindt R, Scheltema RA, Jankevics A, Brunker K, et al. Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis. 2010;4, e904.
Mukherjee B, Mukhopadhyay R, Bannerjee B, Chowdhury S, et al. Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci U S A. 2013;110:E575–82.
Urbina JA, Cohen BE, Perozo E, Cornivelli L. Spin-labeled amphotericin B: synthesis, characterization, biological and spectroscopic properties. Biochim Biophys Acta. 1987;897:467–73.
Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. 1990;34:183–8.
Baginski M, Czub J. Amphotericin B and its new derivatives—mode of action. Curr Drug Metab. 2009;10:459–69.
Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 2002;81:151–7.
Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 1998;42:352–7.
Srivastava P, Prajapati VK, Rai M, Sundar S. Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. J Clin Microbiol. 2011;49:3088–91.
Purkait B, Kumar A, Nandi N, Sardar AH, et al. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother. 2012;56:1031–41.
Purkait B, Singh R, Wasnik K, Das S, et al. Up-regulation of silent information regulator 2 (Sir2) is associated with amphotericin B resistance in clinical isolates of Leishmania donovani. J Antimicrob Chemother. 2015;70:1343–56.
Chawla B, Jhingran A, Panigrahi A, Stuart KD, Madhubala R. Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani. PLoS One. 2011;6, e26660.
Bhandari V, Sundar S, Dujardin JC, Salotra P. Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani. Antimicrob Agents Chemother. 2014;58:2580–5.
Hendrickx S, Boulet G, Mondelaers A, Dujardin JC, et al. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum. Parasitol Res. 2014;113:1875–81.
Rijal S, Ostyn B, Uranw S, Rai K, et al. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis. 2013;56:1530–8.
Troya J, Casquero A, Refoyo E, Fernandez-Guerrero ML, Gorgolas M. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients. Scand J Infect Dis. 2008;40:78–80.
Obonaga R, Fernandez OL, Valderrama L, Rubiano LC, et al. Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. Antimicrob Agents Chemother. 2014;58:144–52.
Imbert L, Ramos RG, Libong D, Abreu S, et al. Identification of phospholipid species affected by miltefosine action in Leishmania donovani cultures using LC-ELSD, LC-ESI/MS, and multivariate data analysis. Anal Bioanal Chem. 2012;402:1169–82.
Luque-Ortega JR, Rivas L. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes. Antimicrob Agents Chemother. 2007;51:1327–32.
Perez-Victoria FJ, Sanchez-Canete MP, Seifert K, Croft SL, et al. Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use. Drug Resist Updat. 2006;9:26–39.
Perez-Victoria FJ, Castanys S, Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother. 2003;47:2397–403.
Perez-Victoria FJ, Sanchez-Canete MP, Castanys S, Gamarro F. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites. J Biol Chem. 2006;281:23766–75.
Cojean S, Houze S, Haouchine D, Huteau F, et al. Leishmania resistance to miltefosine associated with genetic marker. Emerg Infect Dis. 2012;18:704–6.
Perez-Victoria JM, Perez-Victoria FJ, Parodi-Talice A, Jimenez IA, et al. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob Agents Chemother. 2001;45:2468–74.
Castanys-Munoz E, Perez-Victoria JM, Gamarro F, Castanys S. Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement. Antimicrob Agents Chemother. 2008;52:3573–9.
Castanys-Munoz E, Alder-Baerens N, Pomorski T, Gamarro F, Castanys S. A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. Mol Microbiol. 2007;64:1141–53.
BoseDasgupta S, Ganguly A, Roy A, Mukherjee T, Majumder HK. A novel ATP-binding cassette transporter, ABCG6 is involved in chemoresistance of Leishmania. Mol Biochem Parasitol. 2008;158:176–88.
Utaile M, Kassahun A, Abebe T, Hailu A. Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model. Exp Parasitol. 2013;134:68–75.
Berman JD, Lee LS. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J Parasitol. 1984;70:220–5.
Looker DL, Martinez S, Horton JM, Marr JJ. Growth of Leishmania donovani amastigotes in the continuous human macrophage cell line U937: studies of drug efficacy and metabolism. J Infect Dis. 1986;154:323–7.
Ogunkolade BW, Colomb-Valet I, Monjour L, Rhodes-Feuillette A, et al. Interactions between the human monocytic leukaemia THP-1 cell line and Old and New World species of Leishmania. Acta Trop. 1990;47:171–6.
Veras PS, Moulia C, Dauguet C, Tunis CT, et al. Entry and survival of Leishmania amazonensis amastigotes within phagolysosome-like vacuoles that shelter Coxiella burnetii in Chinese hamster ovary cells. Infect Immun. 1995;63:3502–6.
Abdullah SM, Flath B, Presber HW. Comparison of different staining procedures for the flow cytometric analysis of U-937 cells infected with different Leishmania-species. J Microbiol Methods. 1999;37:123–38.
Abdullah SM, Flath B, Presber W. Mixed infection of human U-937 cells by two different species of Leishmania. Am J Trop Med Hyg. 1998;59:182–8.
Bertho AL, Cysne L, Coutinho SG. Flow cytometry in the study of the interaction between murine macrophages and the protozoan parasite Leishmania amazonensis. J Parasitol. 1992;78:666–71.
Di Giorgio C, Ridoux O, Delmas F, Azas N, et al. Flow cytometric detection of Leishmania parasites in human monocyte-derived macrophages: application to antileishmanial-drug testing. Antimicrob Agents Chemother. 2000;44:3074–8.
Hansen BD, Webster HK, Hendricks LD, Pappas MG. Leishmania mexicana: purine metabolism in promastigotes, axenic amastigotes, and amastigotes derived from Vero cells. Exp Parasitol. 1984;58:101–9.
Bates PA. Axenic culture of Leishmania amastigotes. Parasitol Today. 1993;9:143–6.
Gupta N, Goyal N, Rastogi AK. In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol. 2001;17:150–3.
Petropolis DB, Rodrigues JC, Viana NB, Pontes B, et al. Leishmania amazonensis promastigotes in 3D Collagen I culture: an in vitro physiological environment for the study of extracellular matrix and host cell interactions. PeerJ. 2014;2, e317.
Gupta S. Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res. 2011;133:27–39.
Adl SM, Leander BS, Simpson AG, Archibald JM, et al. Diversity, nomenclature, and taxonomy of protists. Syst Biol. 2007;56:684–9.
Mueller I, Slutsker L, Tanner M. Estimating the burden of malaria: the need for improved surveillance. PLoS Med. 2011;8, e1001144.
Alonso PL, Brown G, Arevalo-Herrera M, Binka F, et al. A research agenda to underpin malaria eradication. PLoS Med. 2011;8, e1000406.
Bhaumik S. Malaria funds drying up: World Malaria Report 2012. Natl Med J India. 2013;26:62.
Witkowski B, Amaratunga C, Khim N, Sreng S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013;13:1043–9.
Wangroongsarb P, Satimai W, Khamsiriwatchara A, Thwing J, et al. Respondent-driven sampling on the Thailand-Cambodia border. II. Knowledge, perception, practice and treatment-seeking behaviour of migrants in malaria endemic zones. Malar J. 2011;10:117.
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.
Amaratunga C, Sreng S, Suon S, Phelps ES, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851–8.
Djimde A, Doumbo OK, Cortese JF, Kayentao K, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257–63.
Anderson TJ, Nair S, Qin H, Singlam S, et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance? Antimicrob Agents Chemother. 2005;49:2180–8.
Duraisingh MT, Drakeley CJ, Muller O, Bailey R, et al. Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology. 1997;114(Pt 3):205–11.
Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop. 2005;94:181–90.
Rungsihirunrat K, Muhamad P, Chaijaroenkul W, Kuesap J, Na-Bangchang K. Plasmodium vivax drug resistance genes; Pvmdr1 and Pvcrt-o polymorphisms in relation to chloroquine sensitivity from a malaria endemic area of Thailand. Korean J Parasitol. 2015;53:43–9.
Klokouzas A, Tiffert T, van Schalkwyk D, Wu CP, et al. Plasmodium falciparum expresses a multidrug resistance-associated protein. Biochem Biophys Res Commun. 2004;321:197–201.
Ferdig MT, Cooper RA, Mu J, Deng B, et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol. 2004;52:985–97.
Wendler JP, Okombo J, Amato R, Miotto O, et al. A genome wide association study of Plasmodium falciparum susceptibility to 22 antimalarial drugs in Kenya. PLoS One. 2014;9, e96486.
Veiga MI, Osorio NS, Ferreira PE, Franzen O, et al. Complex polymorphisms in the Plasmodium falciparum multidrug resistance protein 2 gene and its contribution to antimalarial response. Antimicrob Agents Chemother. 2014;58:7390–7.
van der Velden M, Rijpma SR, Russel FG, Sauerwein RW, Koenderink JB. PfMDR2 and PfMDR5 are dispensable for Plasmodium falciparum asexual parasite multiplication but change in vitro susceptibility to anti-malarial drugs. Malar J. 2015;14:76.
Wilson CM, Serrano AE, Wasley A, Bogenschutz MP, et al. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science. 1989;244:1184–6.
Price RN, Uhlemann AC, Brockman A, McGready R, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438–47.
Preechapornkul P, Imwong M, Chotivanich K, Pongtavornpinyo W, et al. Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness. Antimicrob Agents Chemother. 2009;53:1509–15.
Gupta B, Xu S, Wang Z, Sun L, et al. Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar. J Antimicrob Chemother. 2014;69:2110–17.
Heinberg A, Kirkman L. The molecular basis of antifolate resistance in Plasmodium falciparum: looking beyond point mutations. Ann N Y Acad Sci. 2015;1342:10–8.
Fisher N, Abd Majid R, Antoine T, Al-Helal M, et al. Cytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. J Biol Chem. 2012;287:9731–41.
Akhoon BA, Singh KP, Varshney M, Gupta SK, Shukla Y. Understanding the mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation Y268S using computational methods. PLoS One. 2014;9, e110041.
Antoine T, Fisher N, Amewu R, O’Neill PM, et al. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J Antimicrob Chemother. 2014;69:1005–16.
O’Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin--the debate continues. Molecules. 2010;15:1705–21.
White NJ. Malaria: a molecular marker of artemisinin resistance. Lancet. 2014;383:1439–40.
Ariey F, Witkowski B, Amaratunga C, Beghain J, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.
Wang Z, Shrestha S, Li X, Miao J, et al. Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007–2012. Malar J. 2015;14:168.
Serebrennikova YM, Patel J, Milhous WK, Garcia-Rubio LH, et al. Spectrophotometric detection of susceptibility to anti-malarial drugs. Malar J. 2013;12:305.
Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979;16:710–18.
Chaorattanakawee S, Tyner SD, Lon C, Yingyuen K, et al. Direct comparison of the histidine-rich protein-2 enzyme-linked immunosorbent assay (HRP-2 ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity tests in Plasmodium falciparum reference clones and fresh ex vivo field isolates from Cambodia. Malar J. 2013;12:239.
Rason MA, Randriantsoa T, Andrianantenaina H, Ratsimbasoa A, Menard D. Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg. 2008;102:346–51.
Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother. 2006;50:3343–9.
Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am J Trop Med Hyg. 2004;71:711–14.
Cerutti Junior C, Marques C, Alencar FE, Durlacher RR, et al. Antimalarial drug susceptibility testing of Plasmodium falciparum in Brazil using a radioisotope method. Mem Inst Oswaldo Cruz. 1999;94:803–9.
Webster HK, Boudreau EF, Pavanand K, Yongvanitchit K, Pang LW. Antimalarial drug susceptibility testing of Plasmodium falciparum in Thailand using a microdilution radioisotope method. Am J Trop Med Hyg. 1985;34:228–35.
Basco LK, Report of the World Health Organization (WHO). 2007.
Gamboa D, Ho MF, Bendezu J, Torres K, et al. A large proportion of P. falciparum isolates in the Amazon region of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. PLoS One. 2010;5, e8091.
Akinyi S, Hayden T, Gamboa D, Torres K, et al. Multiple genetic origins of histidine-rich protein 2 gene deletion in Plasmodium falciparum parasites from Peru. Sci Rep. 2013;3:2797.
Brasseur P, Agnamey P, Moreno A, Druilhe P. Evaluation of in vitro drug sensitivity of antimalarials for Plasmodium falciparum using a colorimetric assay (DELI-microtest). Med Trop (Mars). 2001;61:545–7.
Dieng T, Bah IB, Ndiaye PM, Diallo I, et al. [In vitro evaluation of the sensitivity of Plasmodium falciparum to chloroquine using the deli-microtest in region of Dakar, Senegal]. Med Trop (Mars). 2005;65:580–3.
Tun KM, Imwong M, Lwin KM, Win AA, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415–21.
Talundzic E, Okoth SA, Congpuong K, Plucinski MM, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog. 2015;11, e1004789.
Mishra N, Prajapati SK, Kaitholia K, Bharti RS, et al. Surveillance of Artemisinin Resistance in Plasmodium falciparum in India Using the kelch13 Molecular Marker. Antimicrob Agents Chemother. 2015;59:2548–53.
Flegr J, Prandota J, Sovickova M, Israili ZH. Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014;9, e90203.
Remington JS, Thulliez P, Montoya JG. Recent developments for diagnosis of toxoplasmosis. J Clin Microbiol. 2004;42:941–5.
Allinson J, Topping W, Edwards SG, Miller RF. Sulphadiazine-induced obstructive renal failure complicating treatment of HIV-associated toxoplasmosis. Int J STD AIDS. 2012;23:210–12.
Faucher B, Moreau J, Zaegel O, Franck J, Piarroux R. Failure of conventional treatment with pyrimethamine and sulfadiazine for secondary prophylaxis of cerebral toxoplasmosis in a patient with AIDS. J Antimicrob Chemother. 2011;66:1654–6.
Durand JM, Cretel E, Bagneres D, Guillemot E, et al. Failure of atovaquone in the treatment of cerebral toxoplasmosis. AIDS. 1995;9:812–13.
Doliwa C, Escotte-Binet S, Aubert D, Sauvage V, et al. Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters. Parasite. 2013;20:19.
Pashley TV, Volpe F, Pudney M, Hyde JE, et al. Isolation and molecular characterization of the bifunctional hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase gene from Toxoplasma gondii. Mol Biochem Parasitol. 1997;86:37–47.
McFadden DC, Tomavo S, Berry EA, Boothroyd JC. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol Biochem Parasitol. 2000;108:1–12.
Doliwa C, Escotte-Binet S, Aubert D, Velard F, et al. Induction of sulfadiazine resistance in vitro in Toxoplasma gondii. Exp Parasitol. 2013;133:131–6.
Derouin F, Chastang C. Enzyme immunoassay to assess effect of antimicrobial agents on Toxoplasma gondii in tissue culture. Antimicrob Agents Chemother. 1988;32:303–7.
Slapeta J. Cryptosporidiosis and Cryptosporidium species in animals and humans: a thirty colour rainbow? Int J Parasitol. 2013;43:957–70.
Bouzid M, Hunter PR, Chalmers RM, Tyler KM. Cryptosporidium pathogenicity and virulence. Clin Microbiol Rev. 2013;26:115–34.
Checkley W, White Jr AC, Jaganath D, Arrowood MJ, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2015;15:85–94.
Benitez AJ, McNair N, Mead J. Modulation of gene expression of three Cryptosporidium parvum ATP-binding cassette transporters in response to drug treatment. Parasitol Res. 2007;101:1611–16.
Castellanos-Gonzalez A, Cabada MM, Nichols J, Gomez G, White Jr AC. Human primary intestinal epithelial cells as an improved in vitro model for Cryptosporidium parvum infection. Infect Immun. 2013;81:1996–2001.
Woods KM, Upton SJ. Efficacy of select antivirals against Cryptosporidium parvum in vitro. FEMS Microbiol Lett. 1998;168:59–63.
Castro-Hermida JA, Ares-Mazas ME. In vitro and in vivo efficacy of alpha-cyclodextrin for treatment of experimental cryptosporidiosis. Vet Parasitol. 2003;114:237–45.
Jenkins MB, Anguish LJ, Bowman DD, Walker MJ, Ghiorse WC. Assessment of a dye permeability assay for determination of inactivation rates of Cryptosporidium parvum oocysts. Appl Environ Microbiol. 1997;63:3844–50.
Sharman PA, Smith NC, Wallach MG, Katrib M. Chasing the golden egg: vaccination against poultry coccidiosis. Parasite Immunol. 2010;32:590–8.
Morris GM, Gasser RB. Biotechnological advances in the diagnosis of avian coccidiosis and the analysis of genetic variation in Eimeria. Biotechnol Adv. 2006;24:590–603.
Morgan JA, Morris GM, Wlodek BM, Byrnes R, et al. Real-time polymerase chain reaction (PCR) assays for the specific detection and quantification of seven Eimeria species that cause coccidiosis in chickens. Mol Cell Probes. 2009;23:83–9.
Li GQ, Kanu S, Xiao SM, Xiang FY. Responses of chickens vaccinated with a live attenuated multi-valent ionophore-tolerant Eimeria vaccine. Vet Parasitol. 2005;129:179–86.
Chapman HD. Drug resistance in avian coccidia (a review). Vet Parasitol. 1984;15:11–27.
Holdsworth PA, Conway DP, McKenzie ME, Dayton AD, et al. World Association for the Advancement of Veterinary Parasitology (WAAVP) guidelines for evaluating the efficacy of anticoccidial drugs in chickens and turkeys. Vet Parasitol. 2004;121:189–212.
Johnson J, Reid WM. Anticoccidial drugs: lesion scoring techniques in battery and floor-pen experiments with chickens. Exp Parasitol. 1970;28:30–6.
Arabkhazaeli F, Modrisanei M, Nabian S, Mansoori B, Madani A. Evaluating the resistance of eimeria spp. Field isolates to anticoccidial drugs using three different indices. Iran J Parasitol. 2013;8:234–41.
Verdier RI, Fitzgerald DW, Johnson Jr WD, Pape JW. Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med. 2000;132:885–8.
Boyles TH, Black J, Meintjes G, Mendelson M. Failure to eradicate Isospora belli diarrhoea despite immune reconstitution in adults with HIV—a case series. PLoS One. 2012;7, e42844.
Gorricho Mendivil J, Torres Sopena L, Paradineiro Somoza JC, Moles Calandre B. Treatment of recurrent Isospora belli diarrhea. Rev Esp Enferm Dig. 1995;87:612–13.
Bialek R, Overkamp D, Rettig I, Knobloch J. Case report: nitazoxanide treatment failure in chronic isosporiasis. Am J Trop Med Hyg. 2001;65:94–5.
Smith J, Garber GE. Current status and prospects for development of a vaccine against Trichomonas vaginalis infections. Vaccine. 2014;32:1588–94.
Hrdy I, Cammack R, Stopka P, Kulda J, Tachezy J. Alternative pathway of metronidazole activation in Trichomonas vaginalis hydrogenosomes. Antimicrob Agents Chemother. 2005;49:5033–6.
Leitsch D, Kolarich D, Binder M, Stadlmann J, et al. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol Microbiol. 2009;72:518–36.
Dunne RL, Dunn LA, Upcroft P, O’Donoghue PJ, Upcroft JA. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res. 2003;13:239–49.
Kirkcaldy RD, Augostini P, Asbel LE, Bernstein KT, et al. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009–2010. Emerg Infect Dis. 2012;18:939–43.
Krashin JW, Koumans EH, Bradshaw-Sydnor AC, Braxton JR, et al. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sex Transm Dis. 2010;37:440–4.
Schwebke JR, Barrientes FJ. Prevalence of Trichomonas vaginalis isolates with resistance to metronidazole and tinidazole. Antimicrob Agents Chemother. 2006;50:4209–10.
Upcroft JA, Upcroft P. Drug susceptibility testing of anaerobic protozoa. Antimicrob Agents Chemother. 2001;45:1810–14.
Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev. 2001;14:150–64.
Townson SM, Boreham PF, Upcroft P, Upcroft JA. Resistance to the nitroheterocyclic drugs. Acta Trop. 1994;56:173–94.
Yarlett N, Gorrell TE, Marczak R, Muller M. Reduction of nitroimidazole derivatives by hydrogenosomal extracts of Trichomonas vaginalis. Mol Biochem Parasitol. 1985;14:29–40.
Kulda J, Kabíçková H, Tachezy J, Çerkasovová A, Çerkasov J. Metronidazole resistant trichomonads: mechanisms of in vitro developed anaerobic resistance. In: Lloyd D, Coombs GH, Paget TAP, editors. Biochemistry and molecular biology of ‘Anaerobic’ protozoa. Chur: Harwood Academic Publishers; 1989. p. 137–60.
Muller M, Gorrell TE. Metabolism and metronidazole uptake in Trichomonas vaginalis isolates with different metronidazole susceptibilities. Antimicrob Agents Chemother. 1983;24:667–73.
Wright JM, Webb RI, O’Donoghue P, Upcroft P, Upcroft JA. Hydrogenosomes of laboratory-induced metronidazole-resistant Trichomonas vaginalis lines are downsized while those from clinically metronidazole-resistant isolates are not. J Eukaryot Microbiol. 2010;57:171–6.
Leitsch D, Kolarich D, Duchene M. The flavin inhibitor diphenyleneiodonium renders Trichomonas vaginalis resistant to metronidazole, inhibits thioredoxin reductase and flavin reductase, and shuts off hydrogenosomal enzymatic pathways. Mol Biochem Parasitol. 2010;171:17–24.
Leitsch D, Drinic M, Kolarich D, Duchene M. Down-regulation of flavin reductase and alcohol dehydrogenase-1 (ADH1) in metronidazole-resistant isolates of Trichomonas vaginalis. Mol Biochem Parasitol. 2012;183:177–83.
Leitsch D, Janssen BD, Kolarich D, Johnson PJ, Duchene M. Trichomonas vaginalis flavin reductase 1 and its role in metronidazole resistance. Mol Microbiol. 2014;91:198–208.
Paulish-Miller TE, Augostini P, Schuyler JA, Smith WL, et al. Trichomonas vaginalis metronidazole resistance is associated with single nucleotide polymorphisms in the nitroreductase genes ntr4Tv and ntr6Tv. Antimicrob Agents Chemother. 2014;58:2938–43.
Meri T, Jokiranta TS, Suhonen L, Meri S. Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations. J Clin Microbiol. 2000;38:763–7.
Brown DM, Upcroft JA, Dodd HN, Chen N, Upcroft P. Alternative 2-keto acid oxidoreductase activities in Trichomonas vaginalis. Mol Biochem Parasitol. 1999;98:203–14.
Kulda J, Tachezy J, Cerkasovova A. In vitro induced anaerobic resistance to metronidazole in Trichomonas vaginalis. J Eukaryot Microbiol. 1993;40:262–9.
Lossick JG, Muller M, Gorrell TE. In vitro drug susceptibility and doses of metronidazole required for cure in cases of refractory vaginal trichomoniasis. J Infect Dis. 1986;153:948–55.
Meingassner JG, Thurner J. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother. 1979;15:254–7.
Thurner J, Meingassner JG. Isolation of Trichomonas vaginalis resistant to metronidazole. Lancet. 1978;2:738.
Boreham PF, Phillips RE, Shepherd RW. The sensitivity of Giardia intestinalis to drugs in vitro. J Antimicrob Chemother. 1984;14:449–61.
Gero AM, Kang EW, Harvey JE, Schofield PJ, et al. Trichomonas vaginalis: detection of nucleoside hydrolase activity as a potential screening procedure. Exp Parasitol. 2000;94:125–8.
Kang EW, Clinch K, Furneaux RH, Harvey JE, et al. A novel and simple colorimetric method for screening Giardia intestinalis and anti-giardial activity in vitro. Parasitology. 1998;117(Pt 3):229–34.
Abraham MC, Desjardins M, Filion LG, Garber GE. Inducible immunity to Trichomonas vaginalis in a mouse model of vaginal infection. Infect Immun. 1996;64:3571–5.
Kulda J. Employment of experimental animals in studies of Trichomonas vaginalis infection. In: Honigberg BM, editor. Trichomonads parasitic in humans. New York: Springer; 1990. p. 112–54.
Patton DL, Sweeney YT, Agnew KJ, Balkus JE, et al. Development of a nonhuman primate model for Trichomonas vaginalis infection. Sex Transm Dis. 2006;33:743–6.
Henning T, Fakile Y, Phillips C, Sweeney E, et al. Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV(SF162P3). J Med Primatol. 2011;40:214–23.
Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. Expert Opin Pharmacother. 2007;8:1885–902.
Gardner TB, Hill DR. Treatment of giardiasis. Clin Microbiol Rev. 2001;14:114–28.
Rosenthal P, Liebman WM. Comparative study of stool examinations, duodenal aspiration, and pediatric Entero-Test for giardiasis in children. J Pediatr. 1980;96:278–9.
Lemee V, Zaharia I, Nevez G, Rabodonirina M, et al. Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J Antimicrob Chemother. 2000;46:819–21.
Upcroft JA, Upcroft P, Boreham PF. Drug resistance in Giardia intestinalis. Int J Parasitol. 1990;20:489–96.
Leitsch D, Burgess AG, Dunn LA, Krauer KG, et al. Pyruvate:ferredoxin oxidoreductase and thioredoxin reductase are involved in 5-nitroimidazole activation while flavin metabolism is linked to 5-nitroimidazole resistance in Giardia lamblia. J Antimicrob Chemother. 2011;66:1756–65.
Smith NC, Bryant C, Boreham PF. Possible roles for pyruvate:ferredoxin oxidoreductase and thiol-dependent peroxidase and reductase activities in resistance to nitroheterocyclic drugs in Giardia intestinalis. Int J Parasitol. 1988;18:991–7.
Muller J, Schildknecht P, Muller N. Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia: characterization of a novel nitroreductase (GlNR2). J Antimicrob Chemother. 2013;68:1781–9.
Nillius D, Muller J, Muller N. Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs. J Antimicrob Chemother. 2011;66:1029–35.
Muller J, Sterk M, Hemphill A, Muller N. Characterization of Giardia lamblia WB C6 clones resistant to nitazoxanide and to metronidazole. J Antimicrob Chemother. 2007;60:280–7.
Upcroft JA, Upcroft P. Drug resistance and Giardia. Parasitol Today. 1993;9:187–90.
Upcroft P. Drug resistance in Giardia: clinical versus laboratory isolates. Drug Resist Updat. 1998;1:166–8.
Lindquist HD. Induction of albendazole resistance in Giardia lamblia. Microb Drug Resist. 1996;2:433–4.
Upcroft J, Mitchell R, Chen N, Upcroft P. Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Microb Drug Resist. 1996;2:303–8.
Arguello-Garcia R, Cruz-Soto M, Gonzalez-Trejo R, Paz-Maldonado LM, et al. An antioxidant response is involved in resistance of Giardia duodenalis to albendazole. Front Microbiol. 2015;6:286.
Ansell BR, McConville MJ, Ma’ayeh SY, Dagley MJ, et al. Drug resistance in Giardia duodenalis. Biotechnol Adv. 2015;33(6 Pt 1):888–901.
Cruz A, Sousa MI, Azeredo Z, Leite E, et al. Isolation, excystation and axenization of Giardia lamblia isolates: in vitro susceptibility to metronidazole and albendazole. J Antimicrob Chemother. 2003;51:1017–20.
Vargas-Villarreal J, Mata-Cardenas BD, Hernandez-Garcia ME, Garza-Gonzalez JN, et al. Modified PEHPS medium as an alternative for the in vitro culture of Giardia lamblia. Biomed Res Int. 2014;2014:714173.
Schupp DG, Januschka MM, Sherlock LA, Stibbs HH, et al. Production of viable Giardia cysts in vitro: determination by fluorogenic dye staining, excystation, and animal infectivity in the mouse and Mongolian gerbil. Gastroenterology. 1988;95:1–10.
Manna D, Dutta PK, Achari B, Lohia A. A novel galacto-glycerolipid from Oxalis corniculata kills Entamoeba histolytica and Giardia lamblia. Antimicrob Agents Chemother. 2010;54:4825–32.
Mata-Cardenas BD, Vargas-Villarreal J, Gonzalez-Salazar F, Palacios-Corona R, Said-Fernandez S. Pharmacologyonline. 2008. p. 529–537.
Busatti HG, Vieira AE, Viana JC, Silva HE, et al. Effect of metronidazole analogues on Giardia lamblia cultures. Parasitol Res. 2007;102:145–9.
Benere E, da Luz RA, Vermeersch M, Cos P, Maes L. A new quantitative in vitro microculture method for Giardia duodenalis trophozoites. J Microbiol Methods. 2007;71:101–6.
Faghiri Z, Santiago RB, Wu Z, Widmer G. High-throughput screening in suboptimal growth conditions identifies agonists of Giardia lamblia proliferation. Parasitology. 2011;138:194–200.
Adagu IS, Nolder D, Warhurst DC, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother. 2002;49:103–11.
McIntyre P, Boreham PF, Phillips RE, Shepherd RW. Chemotherapy in giardiasis: clinical responses and in vitro drug sensitivity of human isolates in axenic culture. J Pediatr. 1986;108:1005–10.
Hill DR, Pohl R, Pearson RD. Giardia lamblia: a culture method for determining parasite viability. Am J Trop Med Hyg. 1986;35:1129–33.
Favennec L, Chochillon C, Magne D, Meillet D, et al. A new screening assay for antigiardial compounds: effects of various drugs on the adherence of Giardia duodenalis to Caco2 cells. Parasitol Res. 1992;78:80–1.
Farbey MD, Reynoldson JA, Thompson RC. In vitro drug susceptibility of 29 isolates of Giardia duodenalis from humans as assessed by an adhesion assay. Int J Parasitol. 1995;25:593–9.
Meloni BP, Thompson RC, Reynoldson JA, Seville P. Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans R Soc Trop Med Hyg. 1990;84:375–9.
Wright CW, Melwani SI, Phillipson JD, Warhurst DC. Determination of anti-giardial activity in vitro by means of soluble formazan production. Trans R Soc Trop Med Hyg. 1992;86:517–19.
Ponce-Macotela M, Gomez-Garduno J, Gonzalez-Maciel A, Reynoso-Robles R, et al. In vitro measurement of nitazoxanide sensitivity of 4 Giardia duodenalis isolates obtained from different hosts. Rev Invest Clin. 2001;53:41–5.
Muller J, Ruhle G, Muller N, Rossignol JF, Hemphill A. In vitro effects of thiazolides on Giardia lamblia WB clone C6 cultured axenically and in coculture with Caco2 cells. Antimicrob Agents Chemother. 2006;50:162–70.
Barbosa J, Rodrigues AG, Perez MJ, Pina-Vaz C. Evaluation of Giardia duodenalis viability after metronidazole treatment by flow cytometry. Mem Inst Oswaldo Cruz. 2014;109:1078–80.
Zheng GX, Zhang XM, Yang YS, Zeng SR, et al. An integrated microfludic device for culturing and screening of Giardia lamblia. Exp Parasitol. 2014;137:1–7.
Benere E, VAN Assche T, Cos P, Maes L. Variation in growth and drug susceptibility among Giardia duodenalis assemblages A, B and E in axenic in vitro culture and in the gerbil model. Parasitology. 2011;138:1354–61.
Deyab FA, El-Nouby KA, Shoheib ZS, El-Fadl AA. Effect of organochlorine (DDT) exposure on experimental giardiasis. J Egypt Soc Parasitol. 2008;38:225–41.
Bansal D, Sehgal R, Chawla Y, Mahajan RC, Malla N. In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar. Ann Clin Microbiol Antimicrob. 2004;3:27.
Pehrson PO, Bengtsson E. A long-term follow up study of amoebiasis treated with metronidazole. Scand J Infect Dis. 1984;16:195–8.
Agrawal P, Gandhi V, Nagral A, Nagral S. An unusual cause of acute liver failure. BMJ Case Rep. 2010. doi:10.1136/bcr.03.2010.2837.
Wassmann C, Hellberg A, Tannich E, Bruchhaus I. Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase. J Biol Chem. 1999;274:26051–6.
Samarawickrema NA, Brown DM, Upcroft JA, Thammapalerd N, Upcroft P. Involvement of superoxide dismutase and pyruvate:ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica. J Antimicrob Chemother. 1997;40:833–40.
Jervis HR, Takeuchi A. Amebic dysentery Animal model: experimental Entamoeba histolytica infection in the germfree guinea pig. Am J Pathol. 1979;94:197–200.
Anaya-Velazquez F, Martinez-Palomo A, Tsutsumi V, Gonzalez-Robles A. Intestinal invasive amebiasis: an experimental model in rodents using axenic or monoxenic strains of Entamoeba histolytica. Am J Trop Med Hyg. 1985;34:723–30.
Arisue N, Hashimoto T, Yoshikawa H, Nakamura Y, et al. Phylogenetic position of Blastocystis hominis and of stramenopiles inferred from multiple molecular sequence data. J Eukaryot Microbiol. 2002;49:42–53.
Elghareeb AS, Younis MS, El Fakahany AF, Nagaty IM, Nagib MM. Laboratory diagnosis of Blastocystis spp. in diarrheic patients. Trop Parasitol. 2015;5:36–41.
Silberman JD, Sogin ML, Leipe DD, Clark CG. Human parasite finds taxonomic home. Nature. 1996;380:398.
Sekar U, Shanthi M. Blastocystis: consensus of treatment and controversies. Trop Parasitol. 2013;3:35–9.
Zaman V, Zaki M. Resistance of Blastocystis hominis cysts to metronidazole. Trop Med Int Health. 1996;1:677–8.
Nasirudeen AM, Hian YE, Singh M, Tan KS. Metronidazole induces programmed cell death in the protozoan parasite Blastocystis hominis. Microbiology. 2004;150:33–43.
Lantsman Y, Tan KS, Morada M, Yarlett N. Biochemical characterization of a mitochondrial-like organelle from Blastocystis sp. subtype 7. Microbiology. 2008;154:2757–66.
Mirza H, Wu Z, Kidwai F, Tan KS. A metronidazole-resistant isolate of Blastocystis spp. is susceptible to nitric oxide and downregulates intestinal epithelial inducible nitric oxide synthase by a novel parasite survival mechanism. Infect Immun. 2011;79:5019–26.
Mirza H, Teo JD, Upcroft J, Tan KS. A rapid, high-throughput viability assay for Blastocystis spp. reveals metronidazole resistance and extensive subtype-dependent variations in drug susceptibilities. Antimicrob Agents Chemother. 2011;55:637–48.
Chai JY. Praziquantel treatment in trematode and cestode infections: an update. Infect Chemother. 2013;45:32–43.
Kyung SY, Cho YK, Kim YJ, Park JW, et al. A paragonimiasis patient with allergic reaction to praziquantel and resistance to triclabendazole: successful treatment after desensitization to praziquantel. Korean J Parasitol. 2011;49:73–7.
Bhargava P. Indian Acad Clin Med. 2001. p. 1–2.
Kwa MS, Veenstra JG, Roos MH. Benzimidazole resistance in Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in beta-tubulin isotype 1. Mol Biochem Parasitol. 1994;63:299–303.
Silvestre A, Cabaret J. Mutation in position 167 of isotype 1 beta-tubulin gene of Trichostrongylid nematodes: role in benzimidazole resistance? Mol Biochem Parasitol. 2002;120:297–300.
Ghisi M, Kaminsky R, Maser P. Phenotyping and genotyping of Haemonchus contortus isolates reveals a new putative candidate mutation for benzimidazole resistance in nematodes. Vet Parasitol. 2007;144:313–20.
Blackhall WJ, Prichard RK, Beech RN. P-glycoprotein selection in strains of Haemonchus contortus resistant to benzimidazoles. Vet Parasitol. 2008;152:101–7.
Kerboeuf D, Guegnard F, Le Vern Y. Analysis and partial reversal of multidrug resistance to anthelmintics due to P-glycoprotein in Haemonchus contortus eggs using Lens culinaris lectin. Parasitol Res. 2002;88:816–21.
Kopp SR, Coleman GT, Traub RJ, McCarthy JS, Kotze AC. Acetylcholine receptor subunit genes from Ancylostoma caninum: altered transcription patterns associated with pyrantel resistance. Int J Parasitol. 2009;39:435–41.
Boulin T, Fauvin A, Charvet CL, Cortet J, et al. Functional reconstitution of Haemonchus contortus acetylcholine receptors in Xenopus oocytes provides mechanistic insights into levamisole resistance. Br J Pharmacol. 2011;164:1421–32.
Barrere V, Beech RN, Charvet CL, Prichard RK. Novel assay for the detection and monitoring of levamisole resistance in Haemonchus contortus. Int J Parasitol. 2014;44:235–41.
Blackhall WJ, Pouliot JF, Prichard RK, Beech RN. Haemonchus contortus: selection at a glutamate-gated chloride channel gene in ivermectin- and moxidectin-selected strains. Exp Parasitol. 1998;90:42–8.
Nana-Djeunga H, Bourguinat C, Pion SD, Kamgno J, et al. Single nucleotide polymorphisms in beta-tubulin selected in Onchocerca volvulus following repeated ivermectin treatment: possible indication of resistance selection. Mol Biochem Parasitol. 2012;185:10–8.
Xu M, Molento M, Blackhall W, Ribeiro P, et al. Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog. Mol Biochem Parasitol. 1998;91:327–35.
Pohl PC, Carvalho DD, Daffre S, Vaz Ida Jr S, Masuda A. In vitro establishment of ivermectin-resistant Rhipicephalus microplus cell line and the contribution of ABC transporters on the resistance mechanism. Vet Parasitol. 2014;204:316–22.
Prichard RK. Ivermectin resistance and overview of the consortium for anthelmintic resistance SNPs. Expert Opin Drug Discov. 2007;2:S41–52.
Wang W, Wang L, Liang YS. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res. 2012;111:1871–7.
Coles GC, Bauer C, Borgsteede FH, Geerts S, et al. World Association for the Advancement of Veterinary Parasitology (W.A.A.V.P.) methods for the detection of anthelmintic resistance in nematodes of veterinary importance. Vet Parasitol. 1992;44:35–44.
Taylor MA, Hunt KR, Goodyear KL. Anthelmintic resistance detection methods. Vet Parasitol. 2002;103:183–94.
Coles GC, Jackson F, Pomroy WE, Prichard RK, et al. The detection of anthelmintic resistance in nematodes of veterinary importance. Vet Parasitol. 2006;136:167–85.
Chandra S, Prasad A, Yadav N, Latchumikanthan A, et al. Status of benzimidazole resistance in Haemonchus contortus of goats from different geographic regions of Uttar Pradesh. India Vet Parasitol. 2015;208:263–7.
Martin PJ, Anderson N, Jarrett RG. Detecting benzimidazole resistance with faecal egg count reduction tests and in vitro assays. Aust Vet J. 1989;66:236–40.
Levecke B, Speybroeck N, Dobson RJ, Vercruysse J, Charlier J. Novel insights in the fecal egg count reduction test for monitoring drug efficacy against soil-transmitted helminths in large-scale treatment programs. PLoS Negl Trop Dis. 2011;5, e1427.
Barda B, Cajal P, Villagran E, Cimino R, et al. Mini-FLOTAC, Kato-Katz and McMaster: three methods, one goal; highlights from north Argentina. Parasit Vectors. 2014;7:271.
Utzinger J, Rinaldi L, Lohourignon LK, Rohner F, et al. FLOTAC: a new sensitive technique for the diagnosis of hookworm infections in humans. Trans R Soc Trop Med Hyg. 2008;102:84–90.
Levecke B, Behnke JM, Ajjampur SS, Albonico M, et al. A comparison of the sensitivity and fecal egg counts of the McMaster egg counting and Kato-Katz thick smear methods for soil-transmitted helminths. PLoS Negl Trop Dis. 2011;5, e1201.
Le Jambre LF. Relationship of blood loss to worm numbers, biomass and egg production in Haemonchus infected sheep. Int J Parasitol. 1995;25:269–73.
Kumba FF, Katjivena H, Kauta G, Lutaaya E. Seasonal evolution of faecal egg output by gastrointestinal worms in goats on communal farms in eastern Namibia. Onderstepoort J Vet Res. 2003;70:265–71.
Johansen MV. An evaluation of techniques used for the detection of anthelmintic resistance in nematode parasites of domestic livestock. Vet Res Commun. 1989;13:455–66.
Chintoan-Uta C, Morgan ER, Skuce PJ, Coles GC. Wild deer as potential vectors of anthelmintic-resistant abomasal nematodes between cattle and sheep farms. Proc Biol Sci. 2014;281:20132985.
Albonico M, Wright V, Ramsan M, Haji HJ, et al. Development of the egg hatch assay for detection of anthelminthic resistance in human hookworms. Int J Parasitol. 2005;35:803–11.
De Clercq D, Sacko M, Behnke J, Gilbert F, et al. Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali. Am J Trop Med Hyg. 1997;57:25–30.
Hubert J, Kerboeuf D. A microlarval development assay for the detection of anthelmintic resistance in sheep nematodes. Vet Rec. 1992;130:442–6.
Gill JH, Redwin JM, van Wyk JA, Lacey E. Avermectin inhibition of larval development in Haemonchus contortus—effects of ivermectin resistance. Int J Parasitol. 1995;25:463–70.
Dolinska M, Konigova A, Letkova V, Molnar L, Varady M. Detection of ivermectin resistance by a larval development test—back to the past or a step forward? Vet Parasitol. 2013;198:154–8.
Martin PJ, Le Jambre LF. Larval paralysis as an in vitro assay of levamisole and morantel tartrate resistance inOstertagia. Vet Sci Comm. 1979;3(1):159–64.
Sutherland IA, Lee DL. A larval paralysis assay for the detection of thiabendazole resistance in trichostrongyles. Parasitology. 1990;100(Pt 1):131–5.
Bennett JL, Pax RA. Micromotility meter: an instrument designed to evaluate the action of drugs on motility of larval and adult nematodes. Parasitology. 1986;93(Pt 2):341–6.
Rothwell JT, Sangster NC. An in vitro assay utilising parasitic larval Haemonchus contortus to detect resistance to closantel and other anthelmintics. Int J Parasitol. 1993;23:573–8.
Gill JH, Redwin JM, van Wyk JA, Lacey E. Detection of resistance to ivermectin in Haemonchus contortus. Int J Parasitol. 1991;21:771–6.
Douch PG, Morum PE. The effects of anthelmintics on ovine larval nematode parasite migration in vitro. Int J Parasitol. 1994;24:321–6.
Gatongi PM, Njoroge JM, Scott ME, Ranjan S, et al. Susceptibility to IVM in a field strain of Haemonchus contortus subjected to four treatments in a closed sheep-goat flock in Kenya. Vet Parasitol. 2003;110:235–40.
Kimambo AE, MacRae JC. Measurement in vitro of a larval migration inhibitory factor in gastrointestinal mucus of sheep made resistant to the roundworm Trichostrongylus colubriformis. Vet Parasitol. 1988;28:213–22.
Rabel B, McGregor R, Douch PG. Improved bioassay for estimation of inhibitory effects of ovine gastrointestinal mucus and anthelmintics on nematode larval migration. Int J Parasitol. 1994;24:671–6.
Wagland BM, Jones WO, Hribar L, Bendixsen T, Emery DL. A new simplified assay for larval migration inhibition. Int J Parasitol. 1992;22:1183–5.
Smout MJ, Kotze AC, McCarthy JS, Loukas A. A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility. PLoS Negl Trop Dis. 2010;4, e885.
Alvarez-Sanchez MA, Perez Garcia J, Bartley D, Jackson F, Rojo-Vazquez FA. The larval feeding inhibition assay for the diagnosis of nematode anthelmintic resistance. Exp Parasitol. 2005;110:56–61.
Tritten L, Braissant O, Keiser J. Comparison of novel and existing tools for studying drug sensitivity against the hookworm Ancylostoma ceylanicum in vitro. Parasitology. 2012;139:348–57.
Schaeffer JM, Stiffey JH, Mrozik H. A chemiluminescent assay for measuring avermectin binding sites. Anal Biochem. 1989;177:291–5.
Lacey E, Snowdon KL. A routine diagnostic assay for the detection of benzimidazole resistance in parasitic nematodes using tritiated benzimidazole carbamates. Vet Parasitol. 1988;27:309–24.
Hulme SE, Shevkoplyas SS, McGuigan AP, Apfeld J, et al. Lifespan-on-a-chip: microfluidic chambers for performing lifelong observation of C. elegans. Lab Chip. 2010;10:589–97.
Rohde CB, Zeng F, Gonzalez-Rubio R, Angel M, Yanik MF. Microfluidic system for on-chip high-throughput whole-animal sorting and screening at subcellular resolution. Proc Natl Acad Sci U S A. 2007;104:13891–5.
Rohde C, Gilleland C, Samara C, Zeng F, Yanik MF. High-throughput in vivo genetic and drug screening using femtosecond laser nano-surgery, and microfluidics. Conf Proc IEEE Eng Med Biol Soc. 2008;2008:2642.
Diawara A, Halpenny CM, Churcher TS, Mwandawiro C, et al. Association between response to albendazole treatment and beta-tubulin genotype frequencies in soil-transmitted helminths. PLoS Negl Trop Dis. 2013;7, e2247.
Diawara A, Drake LJ, Suswillo RR, Kihara J, et al. Assays to detect beta-tubulin codon 200 polymorphism in Trichuris trichiura and Ascaris lumbricoides. PLoS Negl Trop Dis. 2009;3, e397.
Schwenkenbecher JM, Albonico M, Bickle Q, Kaplan RM. Characterization of beta-tubulin genes in hookworms and investigation of resistance-associated mutations using real-time PCR. Mol Biochem Parasitol. 2007;156:167–74.
Phosuk I, Intapan PM, Thanchomnang T, Sanpool O, et al. Molecular detection of Ancylostoma duodenale, Ancylostoma ceylanicum, and Necator americanus in humans in northeastern and southern Thailand. Korean J Parasitol. 2013;51:747–9.
Phuphisut O, Yoonuan T, Sanguankiat S, Chaisiri K, et al. Triplex polymerase chain reaction assay for detection of major soil-transmitted helminths, Ascaris lumbricoides, Trichuris trichiura, Necator americanus, in fecal samples. Southeast Asian J Trop Med Public Health. 2014;45:267–75.
Staudacher O, Heimer J, Steiner F, Kayonga Y, et al. Soil-transmitted helminths in southern highland Rwanda: associated factors and effectiveness of school-based preventive chemotherapy. Trop Med Int Health. 2014;19:812–24.
van Mens SP, Aryeetey Y, Yazdanbakhsh M, van Lieshout L, et al. Comparison of real-time PCR and Kato smear microscopy for the detection of hookworm infections in three consecutive faecal samples from schoolchildren in Ghana. Trans R Soc Trop Med Hyg. 2013;107:269–71.
Kotze AC, Hunt PW, Skuce P, von Samson-Himmelstjerna G, et al. Recent advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance markers and the description of drug/receptor interactions. Int J Parasitol Drugs Drug Resist. 2014;4:164–84.
Sangster NC, Prichard RK, Lacey E. Tubulin and benzimidazole-resistance in Trichostrongylus colubriformis (Nematoda). J Parasitol. 1985;71:645–51.
Lacey E, Prichard RK. Interactions of benzimidazoles (BZ) with tubulin from BZ-sensitive and BZ-resistant isolates of Haemonchus contortus. Mol Biochem Parasitol. 1986;19:171–81.
Lacey E, Snowdon KL, Eagleson GK, Smith EF. Further investigation of the primary mechanism of benzimidazole resistance in Haemonchus contortus. Int J Parasitol. 1987;17:1421–9.
WHO. Schistosomiasis: number of people treated worldwide in 2013. Wkly Epidemiol Rec. 2015;90:25–32.
Kasinathan RS, Morgan WM, Greenberg RM. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol. 2010;173:25–31.
Couto FF, Coelho PM, Araujo N, Kusel JR, et al. Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails. Mem Inst Oswaldo Cruz. 2011;106:153–7.
Lotfy WM, Hishmat MG, El Nashar AS, Abu El Einin HM. Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni. Pharm Biol. 2015;53(8):1214–19.
Zelia OP. Laboratory animal infection in modeling intestinal schistosomiasis. Parazitologiia. 1984;18:368–73.
Stitt LE, Tompkins JB, Dooley LA, Ardelli BF. ABC transporters influence sensitivity of Brugia malayi to moxidectin and have potential roles in drug resistance. Exp Parasitol. 2011;129:137–44.
Eberhard ML, Lammie PJ, Dickinson CM, Roberts JM. Evidence of nonsusceptibility to diethylcarbamazine in Wuchereria bancrofti. J Infect Dis. 1991;163:1157–60.
Hoti SL, Dhamodharan R, Subramaniyan K, Das PK. An allele specific PCR assay for screening for drug resistance among Wuchereria bancrofti populations in India. Indian J Med Res. 2009;130:193–9.
Hoti SL, Subramaniyan K, Das PK. Detection of codon for amino acid 200 in isotype 1 beta-tubulin gene of Wuchereria bancrofti isolates, implicated in resistance to benzimidazoles in other nematodes. Acta Trop. 2003;88:77–81.
Pechgit P, Intarapuk A, Pinyoowong D, Bhumiratana A. Touchdown-touchup nested PCR for low-copy gene detection of benzimidazole-susceptible Wuchereria bancrofti with a Wolbachia endosymbiont imported by migrant carriers. Exp Parasitol. 2011;127:559–68.
Osei-Atweneboana MY, Eng JK, Boakye DA, Gyapong JO, Prichard RK. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet. 2007;369:2021–9.
Awadzi K, Attah SK, Addy ET, Opoku NO, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98:359–70.
Awadzi K, Boakye DA, Edwards G, Opoku NO, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98:231–49.
Roberts LS, Schmidt G, Janovy Jr J. Foundations of parasitology. 6th ed. Boston: McGraw-Hill; 2000. p. 670.
Marquez-Navarro A, Cornejo-Coria Mdel C, Cebada-Lopez F, Sanchez-Manzano RM, et al. Taenia saginata: failure treatment in a child with 5-year long-lasting infection. Gastroenterol Nurs. 2012;35:125–7.
Pretell EJ, Garcia HH, Gilman RH, Saavedra H, Martinez M. Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin Neurol Neurosurg. 2001;103:175–7.
Matos-Silva H, Reciputti BP, Paula EC, Oliveira AL, et al. Experimental encephalitis caused by Taenia crassiceps cysticerci in mice. Arq Neuropsiquiatr. 2012;70:287–92.
Garcia MB, Lledias JP, Perez IG, Tirado VV, et al. Primary super-infection of hydatid cyst—clinical setting and microbiology in 37 cases. Am J Trop Med Hyg. 2010;82:376–8.
Kocer NE, Kibar Y, Guldur ME, Deniz H, Bakir K. A retrospective study on the coexistence of hydatid cyst and aspergillosis. Int J Infect Dis. 2008;12:248–51.
Nazligul Y, Kucukazman M, Akbulut S. Role of chemotherapeutic agents in the management of cystic echinococcosis. Int Surg. 2015;100:112–14.
Pan D, Das S, Bera AK, Bandyopadhyay S, et al. Molecular and biochemical mining of heat-shock and 14-3-3 proteins in drug-induced protoscolices of Echinococcus granulosus and the detection of a candidate gene for anthelmintic resistance. J Helminthol. 2011;85:196–203.
Kotze AC, Lowe A, O’Grady J, Kopp SR, Behnke JM. Dose-response assay templates for in vitro assessment of resistance to benzimidazole and nicotinic acetylcholine receptor agonist drugs in human hookworms. Am J Trop Med Hyg. 2009;81:163–70.
Kopp SR, Coleman GT, McCarthy JS, Kotze AC. Phenotypic characterization of two Ancylostoma caninum isolates with different susceptibilities to the anthelmintic pyrantel. Antimicrob Agents Chemother. 2008;52:3980–6.
Kotze AC, Stein PA, Dobson RJ. Investigation of intestinal nematode responses to naphthalophos and pyrantel using a larval development assay. Int J Parasitol. 1999;29:1093–9.
Puthiyakunnon S, Boddu S, Li Y, Zhou X, et al. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis. 2014;8, e3018.
Ashraf M, Gue CL, Baddour LM. Case report: strongyloidiasis refractory to treatment with ivermectin. Am J Med Sci. 1996;311:178–9.
Shikiya K, Kinjo N, Uehara T, Uechi H, et al. Efficacy of ivermectin against Strongyloides stercoralis in humans. Intern Med. 1992;31:310–12.
Bisoffi Z, Buonfrate D, Angheben A, Boscolo M, et al. Randomized clinical trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis. PLoS Negl Trop Dis. 2011;5, e1254.
Suputtamongkol Y, Premasathian N, Bhumimuang K, Waywa D, et al. Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. PLoS Negl Trop Dis. 2011;5, e1044.
Kotze AC, Clifford S, O’Grady J, Behnke JM, McCarthy JS. An in vitro larval motility assay to determine anthelmintic sensitivity for human hookworm and Strongyloides species. Am J Trop Med Hyg. 2004;71:608–16.
Intapan PM, Prasongdee TK, Laummaunwai P, Sawanyawisuth K, et al. A modified filter paper culture technique for screening of Strongyloides stercoralis ivermectin sensitivity in clinical specimens. Am J Trop Med Hyg. 2006;75:563–4.
Schneider B, Jariwala AR, Periago MV, Gazzinelli MF, et al. A history of hookworm vaccine development. Hum Vaccin. 2011;7:1234–44.
Hawdon JM. Controlling soil-transmitted helminths: time to think inside the box? J Parasitol. 2014;100:166–88.
Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA. 2008;299:1937–48.
Silbereisen A, Tritten L, Keiser J. Exploration of novel in vitro assays to study drugs against Trichuris spp. J Microbiol Methods. 2011;87:169–75.
Wimmersberger D, Tritten L, Keiser J. Development of an in vitro drug sensitivity assay for Trichuris muris first-stage larvae. Parasit Vectors. 2013;6:42.
Diawara A, Schwenkenbecher JM, Kaplan RM, Prichard RK. Molecular and biological diagnostic tests for monitoring benzimidazole resistance in human soil-transmitted helminths. Am J Trop Med Hyg. 2013;88:1052–61.
Patrick DM, Isaac-Renton J. Praziquantel failure in the treatment of Fasciola hepatica. Can J Infect Dis. 1992;3:33–6.
Schubert S, Phetsouvanh R. Praziquantel is mostly ineffective: treatment of fasciola hepatica infection (large liver fluke). Z Arztl Fortbild (Jena). 1990;84:705–7.
Valero MA, Periago MV, Perez-Crespo I, Angles R, et al. Field evaluation of a coproantigen detection test for fascioliasis diagnosis and surveillance in human hyperendemic areas of Andean countries. PLoS Negl Trop Dis. 2012;6, e1812.
Zumaquero-Rios JL, Sarracent-Perez J, Rojas-Garcia R, Rojas-Rivero L, et al. Fascioliasis and intestinal parasitoses affecting schoolchildren in Atlixco, Puebla State, Mexico: epidemiology and treatment with nitazoxanide. PLoS Negl Trop Dis. 2013;7, e2553.
Dalchow W, Horchner F. Experimental infection with Fasciola hepatica in various animal species. Berl Munch Tierarztl Wochenschr. 1972;85:271–4.
Urdea M, Penny LA, Olmsted SS, Giovanni MY, et al. Requirements for high impact diagnostics in the developing world. Nature. 2006;444 Suppl 1:73–9.
Mabey D, Peeling RW, Ustianowski A, Perkins MD. Diagnostics for the developing world. Nat Rev Microbiol. 2004;2:231–40.
Thekisoe OM, Inoue N, Kuboki N, Tuntasuvan D, et al. Evaluation of loop-mediated isothermal amplification (LAMP), PCR and parasitological tests for detection of Trypanosoma evansi in experimentally infected pigs. Vet Parasitol. 2005;130:327–30.
Kuboki N, Inoue N, Sakurai T, Di Cello F, et al. Loop-mediated isothermal amplification for detection of African trypanosomes. J Clin Microbiol. 2003;41:5517–24.
Poole CB, Tanner NA, Zhang Y, Evans Jr TC, Carlow CK. Diagnosis of brugian filariasis by loop-mediated isothermal amplification. PLoS Negl Trop Dis. 2012;6, e1948.
Polley SD, Gonzalez IJ, Mohamed D, Daly R, et al. Clinical evaluation of a loop-mediated amplification kit for diagnosis of imported malaria. J Infect Dis. 2013;208:637–44.
Poon LL, Wong BW, Ma EH, Chan KH, et al. Sensitive and inexpensive molecular test for falciparum malaria: detecting Plasmodium falciparum DNA directly from heat-treated blood by loop-mediated isothermal amplification. Clin Chem. 2006;52:303–6.
Buates S, Bantuchai S, Sattabongkot J, Han ET, et al. Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) for clinical detection of Plasmodium falciparum gametocytes. Parasitol Int. 2010;59:414–20.
Dinzouna-Boutamba SD, Yang HW, Joo SY, Jeong S, et al. The development of loop-mediated isothermal amplification targeting alpha-tubulin DNA for the rapid detection of Plasmodium vivax. Malar J. 2014;13:248.
Hsiang MS, Greenhouse B, Rosenthal PJ. Point of care testing for malaria using LAMP, loop mediated isothermal amplification. J Infect Dis. 2014;210:1167–9.
Takagi H, Itoh M, Kasai S, Yahathugoda TC, et al. Development of loop-mediated isothermal amplification method for detecting Wuchereria bancrofti DNA in human blood and vector mosquitoes. Parasitol Int. 2011;60:493–7.
Chaouch M, Mhadhbi M, Adams ER, Schoone GJ, et al. Development and evaluation of a loop-mediated isothermal amplification assay for rapid detection of Leishmania infantum in canine leishmaniasis based on cysteine protease B genes. Vet Parasitol. 2013;198:78–84.
Takagi H, Itoh M, Islam MZ, Razzaque A, et al. Sensitive, specific, and rapid detection of Leishmania donovani DNA by loop-mediated isothermal amplification. Am J Trop Med Hyg. 2009;81:578–82.
Verma S, Avishek K, Sharma V, Negi NS, et al. Application of loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis. Diagn Microbiol Infect Dis. 2013;75:390–5.
Adams ER, Schoone GJ, Ageed AF, Safi SE, Schallig HD. Development of a reverse transcriptase loop-mediated isothermal amplification (LAMP) assay for the sensitive detection of Leishmania parasites in clinical samples. Am J Trop Med Hyg. 2010;82:591–6.
Khan MG, Bhaskar KR, Salam MA, Akther T, et al. Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for detection of Leishmania DNA in buffy coat from visceral leishmaniasis patients. Parasit Vectors. 2012;5:280.
Abdul-Ghani R. Towards rapid genotyping of resistant malaria parasites: could loop-mediated isothermal amplification be the solution? Malar J. 2014;13:237.
Martinez AW, Phillips ST, Butte MJ, Whitesides GM. Patterned paper as a platform for inexpensive, low-volume, portable bioassays. Angew Chem Int Ed Engl. 2007;46:1318–20.
Carrilho E, Martinez AW, Whitesides GM. Understanding wax printing: a simple micropatterning process for paper-based microfluidics. Anal Chem. 2009;81:7091–5.
Costa MN, Veigas B, Jacob JM, Santos DS, et al. A low cost, safe, disposable, rapid and self-sustainable paper-based platform for diagnostic testing: lab-on-paper. Nanotechnology. 2014;25:094006.
WHO. The World Health Organization, World health report. Geneva: WHO; 2010.
Mejia R, Vicuna Y, Broncano N, Sandoval C, et al. A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. Am J Trop Med Hyg. 2013;88:1041–7.
Bavarva JH, Bavarva MJ, Karunasena E. Next in line in next-generation sequencing: are we there yet? Pharmacogenomics. 2015;16:1–4.
Oliver GR, Hart SN, Klee EW. Bioinformatics for clinical next generation sequencing. Clin Chem. 2015;61:124–35.
Barzon L, Lavezzo E, Costanzi G, Franchin E, et al. Next-generation sequencing technologies in diagnostic virology. J Clin Virol. 2013;58:346–50.
Capobianchi MR, Giombini E, Rozera G. Next-generation sequencing technology in clinical virology. Clin Microbiol Infect. 2013;19:15–22.
Wain J, Mavrogiorgou E. Next-generation sequencing in clinical microbiology. Expert Rev Mol Diagn. 2013;13:225–7.
Neafsey DE. Genome sequencing sheds light on emerging drug resistance in malaria parasites. Nat Genet. 2013;45:589–90.
Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363–5.
Wasson J, Skolnick G, Love-Gregory L, Permutt MA. Assessing allele frequencies of single nucleotide polymorphisms in DNA pools by pyrosequencing technology. Biotechniques. 2002;32:1144–6, 1148, 1150 passim.
Cheesman S, Creasey A, Degnan K, Kooij T, et al. Validation of Pyrosequencing for accurate and high throughput estimation of allele frequencies in malaria parasites. Mol Biochem Parasitol. 2007;152:213–19.
Edvinsson B, Darde ML, Pelloux H, Evengard B. Rapid genotyping of Toxoplasma gondii by pyrosequencing. Clin Microbiol Infect. 2007;13:424–9.
Geiger C, Compaore G, Coulibaly B, Sie A, et al. Substantial increase in mutations in the genes pfdhfr and pfdhps puts sulphadoxine-pyrimethamine-based intermittent preventive treatment for malaria at risk in Burkina Faso. Trop Med Int Health. 2014;19:690–7.
Stensvold CR, Traub RJ, von Samson-Himmelstjerna G, Jespersgaard C, et al. Blastocystis: subtyping isolates using pyrosequencing technology. Exp Parasitol. 2007;116:111–19.
Zhang H, Ehrenkaufer GM, Hall N, Singh U. Small RNA pyrosequencing in the protozoan parasite Entamoeba histolytica reveals strain-specific small RNAs that target virulence genes. BMC Genomics. 2013;14:53.
Cantacessi C, Giacomin P, Croese J, Zakrzewski M, et al. Impact of experimental hookworm infection on the human gut microbiota. J Infect Dis. 2014;210:1431–4.
Demeler J, Kruger N, Krucken J, von der Heyden VC, et al. Phylogenetic characterization of beta-tubulins and development of pyrosequencing assays for benzimidazole resistance in cattle nematodes. PLoS One. 2013;8, e70212.
von Samson-Himmelstjerna G, Walsh TK, Donnan AA, Carriere S, et al. Molecular detection of benzimidazole resistance in Haemonchus contortus using real-time PCR and pyrosequencing. Parasitology. 2009;136:349–58.
McNamara DT, Kasehagen LJ, Grimberg BT, Cole-Tobian J, et al. Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. Am J Trop Med Hyg. 2006;74:413–21.
Taniuchi M, Verweij JJ, Noor Z, Sobuz SU, et al. High throughput multiplex PCR and probe-based detection with Luminex beads for seven intestinal parasites. Am J Trop Med Hyg. 2011;84:332–7.
Beckmann C, Heininger U, Marti H, Hirsch HH. Gastrointestinal pathogens detected by multiplex nucleic acid amplification testing in stools of pediatric patients and patients returning from the tropics. Infection. 2014;42:961–70.
Wessels E, Rusman LG, van Bussel MJ, Claas EC. Added value of multiplex Luminex Gastrointestinal Pathogen Panel (xTAG(R) GPP) testing in the diagnosis of infectious gastroenteritis. Clin Microbiol Infect. 2014;20:O182–7.
Mikhailovich V, Gryadunov D, Kolchinsky A, Makarov AA, Zasedatelev A. DNA microarrays in the clinic: infectious diseases. Bioessays. 2008;30:673–82.
Zhang G, Cai F, Zhou Z, DeVos J, et al. Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay. J Clin Microbiol. 2013;51:3666–74.
Masimba P, Gare J, Klimkait T, Tanner M, Felger I. Development of a simple microarray for genotyping HIV-1 drug resistance mutations in the reverse transcriptase gene in rural Tanzania. Trop Med Int Health. 2014;19:664–71.
Linger Y, Kukhtin A, Golova J, Perov A, et al. Simplified microarray system for simultaneously detecting rifampin, isoniazid, ethambutol, and streptomycin resistance markers in Mycobacterium tuberculosis. J Clin Microbiol. 2014;52:2100–7.
Moure R, Espanol M, Tudo G, Vicente E, et al. Characterization of the embB gene in Mycobacterium tuberculosis isolates from Barcelona and rapid detection of main mutations related to ethambutol resistance using a low-density DNA array. J Antimicrob Chemother. 2014;69:947–54.
Guimond C, Trudel N, Brochu C, Marquis N, et al. Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. Nucleic Acids Res. 2003;31:5886–96.
Leprohon P, Legare D, Girard I, Papadopoulou B, Ouellette M. Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites. Eukaryot Cell. 2006;5:1713–25.
do Monte-Neto RL, Coelho AC, Raymond F, Legare D, et al. Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl Trop Dis. 2011;5, e1167.
Ornatsky O, Bandura D, Baranov V, Nitz M, et al. Highly multiparametric analysis by mass cytometry. J Immunol Methods. 2010;361:1–20.
Krutzik PO, Clutter MR, Trejo A, Nolan GP. Fluorescent cell barcoding for multiplex flow cytometry. Curr Protoc Cytom. 2011; Chapter 6, Unit 6 31.
Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods. 2006;3:361–8.
Bodenmiller B, Zunder ER, Finck R, Chen TJ, et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012;30:858–67.
Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505–10.
Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990;346:818–22.
Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, et al. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis (Edinb). 2014;94:187–96.
Gold L, Ayers D, Bertino J, Bock C, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One. 2010;5, e15004.
Li N, Wang Y, Pothukuchy A, Syrett A, et al. Aptamers that recognize drug-resistant HIV-1 reverse transcriptase. Nucleic Acids Res. 2008;36:6739–51.
Turek D, Van Simaeys D, Johnson J, Ocsoy I, Tan W. Molecular recognition of live cells using DNA aptamers. World J Transl Med. 2013;2:67–74.
Bruno JG, Richarte AM, Phillips T, Savage AA, et al. Development of a fluorescent enzyme-linked DNA aptamer-magnetic bead sandwich assay and portable fluorometer for sensitive and rapid leishmania detection in sandflies. J Fluoresc. 2014;24:267–77.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Légaré, D., Ouellette, M. (2017). Drug Resistance Assays for Parasitic Diseases. In: Mayers, D., Sobel, J., Ouellette, M., Kaye, K., Marchaim, D. (eds) Antimicrobial Drug Resistance. Springer, Cham. https://doi.org/10.1007/978-3-319-47266-9_36
Download citation
DOI: https://doi.org/10.1007/978-3-319-47266-9_36
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-47264-5
Online ISBN: 978-3-319-47266-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)